Combination vaccine for administration to adolescents

Details Combination vaccine for administration to adolescents Combination vaccine for administration to adolescents

2006-09-05

2006-09-05

Salimi, Ali R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S278100, C530S300000, C435S006120

Reexamination Certificate

active

07101560

ABSTRACT:
Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, aToxoplasma gondiiantigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

REFERENCES:
patent: 5151023 (1992-09-01), Kuzuhara et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6123948 (2000-09-01), Whittle et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 689454 (1994-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 96/26277 (1996-08-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/45957 (1999-09-01), None
patent: WO 00/15255 (2000-03-01), None
patent: WO 00/23105 (2000-04-01), None
patent: WO/44944 (2000-07-01), None
Thompson et al (Biochemical Society Transactions, 1997, 274S).
Roden et al., “Assessment of the SerologicalRelatedness of Genital Human Papillomaviruses by Hemagglutination Inhibition”, Journal of Virology, vol. 70, n0.5, May 1996, pp. 3298-3301.
Wheeler, “Preventive Vaccines for Cervical Cancer”, Salud Publica De Mexico, vol. 39, No. 4, Jul. 1997, pp. 283-287.
Schiller et al., “Papillomavirus-Like Particles and HPV Vaccine Development”, Seminars in Cancer biology, Saunders Scientific Publications, vol. 7, No. 6, pp. 373-382.
Suzich et al., “Systemtic immunication with papilomavirus L1 protein completely prevents the development of viral mucosal papillomas”, Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 92, 1995, pp. 11553-11557.
Lowe et al., “Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-Like Particles Expressed in Yeast”, Journal of Infectious Diseases, vol. 176, No. 5, 1997 pp. 1141-1145.
U.S. Appl. No. 09/807,657, filed Apr. 16, 2001, Garcon.
Breitburd et al., Immunization with Virus-Like Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection, Journal of Virology, vol. 69, (1995), pp. 3959-3963.
Harper et al., Lancet, vol. 364, (2004), pp. 1757-1765.
Kirnbauer et al., Virus-Like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization, Virology, vol. 219, (1996), pp. 37-44.
Kirnbauer et al., Papillomavirus L1 Major Capsid Protein Self-Assembles into Virus-Like Particles that are Highly Immunogenic, PNAS, (1992), vol. 89, pp. 12180-12184.

Affiliated with

Also associated with

Rating

Combination vaccine for administration to adolescents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination vaccine for administration to adolescents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination vaccine for administration to adolescents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3612268